Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1791
- Phase 1/Phase 2478
- Phase 3344
- Phase 4125
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia280
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts102
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT07287618Recruiting
Checking potassium and calcium in a finger-prick blood sample
This study checks if a new way of measuring potassium and calcium from a small drop of blood (like a finger prick) works well. If you're at least 18 and willing to give a tiny blood sample, you can help improve these tests.
Albuquerque, New MexicoAges 18 years+ - NCT06764017RecruitingPhase 2
New combination therapy for elderly lymphoma unable to handle chemo
This trial tests a new treatment called CHiR for people 70 or older with a type of lymphoma (DLBCL) who are either too frail for standard chemo or choose not to have it. The study aims to see if this therapy can work as a gentler option.
Ningbo, ZhejiangAges 70–100 - NCT07283679RecruitingPhase 1/Phase 2
NK cell therapy with two immune agents for returning lymphoma
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
Houston, TexasAges 18 years+ - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+ - NCT07285668Recruiting
Special donor immune cells after stem cell transplant for high-risk blood cancers
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Madison, WisconsinAges 18–80 - NCT07283224Recruiting
Using existing data to improve multiple myeloma care
This study uses already collected, de-identified data from past multiple myeloma trials to learn more about the disease. It does not involve any new treatments or procedures.
Bologna, BoAges 18 years+ - NCT07283822RecruitingPhase 2
Pembrolizumab and Ruxolitinib for Lymphoma
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
New York, New YorkAges 18–95 - NCT07280494RecruitingPhase 1
CD7-targeted CAR-T for MRD after transplant
This trial tests a special immune cell therapy (CAR-T) that targets CD7, a protein found on T-cell leukemia and lymphoma cells. It is for people who have very small amounts of cancer remaining after a stem cell transplant.
Beijing, ChinaAges 3–80 - NCT07281781RecruitingPhase 1/Phase 2
Nelfinavir for anemia in myelofibrosis
This study tests whether an old HIV drug, nelfinavir, can help treat anemia (low red blood cells) in people with myelofibrosis. The goal is to help your bone marrow use iron better so you may have more energy and need fewer blood transfusions.
Orange, CaliforniaAges 18 years+ - NCT07283094RecruitingPhase 1
FHD-286 with decitabine and venetoclax for AML
This early-phase trial tests a new study drug called FHD-286 combined with two standard AML medicines (decitabine and venetoclax). It is for people with a high-risk type of AML that is either newly diagnosed (and you cannot have strong chemotherapy) or has come back after one prior treatment.
The Bronx, New YorkAges 18 years+ - NCT07278921Recruiting
Mosunetuzumab for relapsed follicular lymphoma
This trial tests a drug called Mosunetuzumab for people with follicular lymphoma that has come back or stopped responding after at least two previous treatments. It is available through a compassionate use program for those who have no other options.
MilanAges 18 years+ - NCT07284641RecruitingPhase 2
Stem cell transplant for immune disorders
This trial tests a stem cell transplant to treat common variable immunodeficiency (CVID) and other immune problems. It aims to replace a faulty immune system with a healthy one from a donor.
Pittsburgh, PennsylvaniaAges 5–40 - NCT07285889RecruitingPhase 1/Phase 2
Jaktinib as first treatment for acute graft-versus-host disease
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07285590RecruitingPhase 2
Testing pirtobrutinib and rituximab for mantle cell lymphoma
This trial tests a new drug combination (pirtobrutinib plus rituximab) for people with mantle cell lymphoma who have not yet received any treatment and do not have symptoms. The goal is to see if the combination is safe and effective.
Lisbon, Lisbon DistrictAges 18 years+ - NCT07285239RecruitingPhase 3
Comparing two drug combinations for newly diagnosed multiple myeloma
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
La Crosse, WisconsinAges 18–79 - NCT06883604Recruiting
Proton therapy for early-stage Hodgkin lymphoma
This trial tests if proton beam radiation can effectively treat Hodgkin lymphoma while reducing side effects. It is for people with early-stage disease who have already completed chemotherapy and need radiation.
GothenburgAges 18–60 - NCT04513639RecruitingPhase 2/Phase 3
Checking treatment for multiple myeloma after MRD becomes negative
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
ÅlesundAges 18–75 - NCT05057468RecruitingPhase 3
Second-line treatment for warm autoimmune anemia
This Phase 3 study tests a second-line treatment for adults with warm autoimmune hemolytic anemia whose disease is not controlled with steroids, who cannot tolerate steroids, or who decline standard treatment. It aims to improve anemia and reduce ongoing red blood cell destruction caused by the immune system.
Asyut, Asyut GovernorateAges 18 years+ - NCT05828459RecruitingPhase 1
Testing a new anti-cancer drug in advanced cancers
This early Phase 1 study tests OT-A201 (a first-time-in-humans drug) in people with certain relapsed or advanced cancers. It helps doctors learn the safest dose and how the treatment may work for cancers that have already been treated.
MontpellierAges 18 years+ - NCT06458504Recruiting
HIV infection and bone marrow health study
This study looks at how HIV infection affects the bone marrow's ability to make blood cells. Researchers will use bone marrow samples already taken from HIV-positive patients and compare them to samples from people without HIV.
Boulogne-BillancourtAges 18 years+ - NCT06758375RecruitingPhase 2
Low dose teclistamab for newly diagnosed multiple myeloma
This trial tests a lower dose of the drug teclistamab in people newly diagnosed with multiple myeloma. It aims to see if a lower dose is still effective and has fewer side effects.
Monterrey, Nuevo LeónAges 18 years+ - NCT06886074RecruitingPhase 2
Short blinatumomab to clear leftover B-ALL cells
This trial tests if a shorter course of blinatumomab can remove minimal residual disease (MRD) — tiny traces of leukemia not seen under a microscope — in people with B-cell acute lymphoblastic leukemia after initial treatment.
Monterrey, Nuevo LeónAges 16–60 - NCT06885476Recruiting
NK cell infusion for AML patients with minimal cancer left
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
Bologna, BOAges 18 years+ - NCT06886425Recruiting
Study of how azacytidine works in blood cancers
This study looks at how certain enzymes in your body affect the way a drug called azacytidine works against blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The goal is to better understand who might benefit most from this treatment.
MarseilleAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,288 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.